New Systemic Therapies in Hepatocellular Carcinoma Multi part
Course Information
The learner will receive 0.5 credits upon selecting and completing the individual course. 

    • For over a decade, sorafenib was the only systemic agent available for the treatment of advanced hepatocellular carcinoma (HCC). However, the past 2.5 years has added 6 additional agents. In this Clinical ForumSM, our multidisciplinary expert roundtable convenes to discuss their collaborative care strategies for first and subsequent line management of HCC using case-based scenarios.
Availability: On-Demand
Available May 19, 2020 to Dec 19, 2020
Cost: FREE
Credit Offered: 0.5 AMA PRA Category 1 Credit Credit
1 Attendance Credit Credit